[EFFECT] AVENUE THERAPEUTICS, INC. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

EFFECT

12/17/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	December 16, 2025

Accession Number:

0001104659-25-121247

Submission Type:

POS AM

CIK:	0001644963
Company Name:	AVENUE THERAPEUTICS, INC.
File Number:	333-279125

Source: View Original Filing on SEC EDGAR

Avenue Therapeutics Inc

OTC:ATXI

ATXI Rankings

#6796 Ranked by Market Cap

N/A Ranked by Dividends

ATXI Latest News

Nov 6, 2025

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Nov 14, 2024

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Oct 9, 2024

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

Sep 3, 2024

Avenue Therapeutics to Participate in Upcoming Investor Conferences

Aug 9, 2024

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

ATXI Latest SEC Filings

Jan 6, 2026

[SCHEDULE 13D/A] AVENUE THERAPEUTICS, INC. SEC Filing

Jan 6, 2026

[Form 4] AVENUE THERAPEUTICS, INC. Insider Trading Activity

Dec 31, 2025

[8-K] AVENUE THERAPEUTICS, INC. Reports Material Event

Dec 15, 2025

[POS AM] AVENUE THERAPEUTICS, INC. SEC Filing

Dec 15, 2025

[RW] AVENUE THERAPEUTICS, INC. SEC Filing

ATXI Stock Data

Market Cap 2.79M

Float 2.83M

Insiders Ownership 18.41%

Institutions Ownership 3.15%

Short Percent 2.83%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City BAY HARBOR ISLANDS